Reliance Steel & Aluminum Co (RS) to pay $0.55 on Jun 14, 2019; Cyclacel Pharmaceuticals (CYCC) SI Decreased By 0.79%

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Logo

Reliance Steel & Aluminum Co (NYSE:RS) is expected to pay $0.55 on Jun 14, 2019. (NYSE:RS) shareholders before May 23, 2019 will receive the $0.55 dividend. Reliance Steel & Aluminum Co’s current price of $88.98 translates into 0.62% yield. Reliance Steel & Aluminum Co’s dividend has May 24, 2019 as record date. Apr 25, 2019 is the announcement. The stock increased 2.25% or $1.96 during the last trading session, reaching $88.98. About 520,736 shares traded or 13.07% up from the average. Reliance Steel & Aluminum Co. (NYSE:RS) has declined 4.28% since May 15, 2018 and is downtrending. It has underperformed by 8.65% the S&P500. Some Historical RS News: 26/04/2018 – RELIANCE STEEL & ALUMINUM CO – “METAL PRICING ENVIRONMENT REMAINED VERY STRONG THROUGHOUT QUARTER”; 05/03/2018 – Dir Sharkey III Gifts 500 Of Reliance Steel & Aluminum Co; 27/04/2018 – RELIANCE STEEL & ALUMINUM CO RS.N : DEUTSCHE BANK RAISES TARGET PRICE TO $100 FROM $98; 26/04/2018 – RELIANCE STEEL & ALUMINUM – MAINTAINS POSITIVE OUTLOOK FOR AEROSPACE AS BUILD RATES AND BACKLOG FOR ORDERS OF COMMERCIAL PLANES CONTINUES TO IMPROVE; 26/04/2018 – Reliance Steel Closes Above 50-Day Moving Average: Technicals; 26/04/2018 – Reliance Steel 1Q Adj EPS $2.30; 26/04/2018 – Reliance Steel 1Q EPS $2.30; 17/04/2018 – DEEP ECO: Reliance Steel May Face Pressure, Iron and Steel Down; 16/03/2018 – Reliance Steel May Face Pressure, Industry Slowest in 16 Months; 26/04/2018 – Reliance Steel 1Q Net $169M

Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) had a decrease of 0.79% in short interest. CYCC’s SI was 149,800 shares in May as released by FINRA. Its down 0.79% from 151,000 shares previously. With 65,000 avg volume, 2 days are for Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC)’s short sellers to cover CYCC’s short positions. The SI to Cyclacel Pharmaceuticals Inc’s float is 1.47%. The stock increased 0.71% or $0.0049 during the last trading session, reaching $0.6999. About 35,055 shares traded. Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) has declined 44.97% since May 15, 2018 and is downtrending. It has underperformed by 49.34% the S&P500. Some Historical CYCC News: 17/04/2018 – Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia; 22/04/2018 – DJ Cyclacel Pharmaceuticals Inc, Inst Holders, 1Q 2018 (CYCC); 17/04/2018 – CYCLACEL’S CYC065 CDK INHIBITOR SHOWS SYNERGY WITH VENETOCLAX; 17/04/2018 – CYCLACEL REPORTS PRECLINICAL DATA ON CDK2/9 INHIBITOR; 17/04/2018 – Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia; 16/04/2018 – Cyclacel Pharmaceuticals: Will Soon Start Clinical Study Testing CYC065 Combined With Venetoclax in Patients With Relapsed/refractory Chronic Lymphocytic Leukemia; 16/04/2018 Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting; 16/04/2018 – Cyclacel Announces Results of Phase 1 Clinical Data for CDK Inhibitor CYC065; 16/04/2018 – Cyclacel Pharmaceuticals: CYC065 Effective in Suppressing Cancer Survival Protein Mcl-1 in Peripheral Blood for at Least 24 Hours

Reliance Steel & Aluminum Co. operates as a metals service center firm in the United States and internationally. The company has market cap of $5.98 billion. The firm provides steel, aluminum, stainless, and specialty metals and related processing services to clients in various industries, such as infrastructure and energy; fabricates steel and aluminum products; and provides various precision fabrication services, including laser cutting, shearing, computer numerated control punching, and CNC forming and rolling, as well as welding, assembly, painting, inventory management, and engineering expertise. It has a 9.65 P/E ratio. It also makes metal parts that have applications in various end markets, including industrial machinery, automotive, aerospace, sugar products, and consumer electronics manufacturers.

More notable recent Reliance Steel & Aluminum Co. (NYSE:RS) news were published by: Benzinga.com which released: “Earnings Scheduled For April 25, 2019 – Benzinga” on April 25, 2019, also 247Wallst.com with their article: “China Trade Settlement Could Be Huge for Steel Stocks: 4 to Buy – 24/7 Wall St.” published on April 17, 2019, Globenewswire.com published: “Report: Exploring Fundamental Drivers Behind United Natural Foods, Reliance Steel & Aluminum, TELUS, and Acme United — New Horizons, Emerging Trends, and Upcoming Developments – GlobeNewswire” on May 02, 2019. More interesting news about Reliance Steel & Aluminum Co. (NYSE:RS) were released by: Nasdaq.com and their article: “Reliance Steel & Aluminum Co. to Announce First Quarter 2019 Results on Thursday, April 25th – Nasdaq” published on April 11, 2019 as well as Finance.Yahoo.com‘s news article titled: “Here is What Hedge Funds Think About Farfetch Limited (FTCH) – Yahoo Finance” with publication date: April 23, 2019.

Among 2 analysts covering Reliance Steel \u0026 Aluminum (NYSE:RS), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Reliance Steel \u0026 Aluminum had 4 analyst reports since December 13, 2018 according to SRatingsIntel. The company was upgraded on Thursday, December 13 by Bank of America.

Investors sentiment decreased to 0.56 in Q4 2018. Its down 0.50, from 1.06 in 2018Q3. It dived, as 46 investors sold Reliance Steel & Aluminum Co. shares while 140 reduced holdings. 33 funds opened positions while 72 raised stakes. 56.12 million shares or 1.66% less from 57.07 million shares in 2018Q3 were reported. Fifth Third Financial Bank reported 181 shares. Public Employees Retirement Association Of Colorado holds 0.01% or 12,659 shares. Cubist Systematic Strategies Ltd Co holds 0.02% of its portfolio in Reliance Steel & Aluminum Co. (NYSE:RS) for 7,046 shares. Jefferies Gru Ltd Liability Corporation holds 0% or 2,860 shares in its portfolio. First Hawaiian Bancshares owns 0% invested in Reliance Steel & Aluminum Co. (NYSE:RS) for 1,027 shares. 57 are owned by Tci Wealth Advsr. Eqis Cap Management stated it has 9,137 shares or 0.05% of all its holdings. Northpointe Capital Ltd Limited Liability Company owns 23,772 shares. Grantham Mayo Van Otterloo & has 0.03% invested in Reliance Steel & Aluminum Co. (NYSE:RS) for 58,940 shares. Strs Ohio, a Ohio-based fund reported 6,307 shares. Ny State Common Retirement Fund holds 0.03% in Reliance Steel & Aluminum Co. (NYSE:RS) or 283,910 shares. Chicago Equity Partners Ltd Company reported 0.1% in Reliance Steel & Aluminum Co. (NYSE:RS). Prudential Public Ltd Co invested in 256,150 shares or 0.07% of the stock. Lord Abbett And Commerce Limited Liability Corp owns 823,563 shares. Stone Ridge Asset Management has 0.08% invested in Reliance Steel & Aluminum Co. (NYSE:RS) for 19,419 shares.

Since November 20, 2018, it had 0 buys, and 2 selling transactions for $2.69 million activity. 5,582 shares were sold by Smith William A II, worth $440,866. $2.25M worth of stock was sold by HANNAH DAVID H on Wednesday, November 21.

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company has market cap of $12.04 million. The companyÂ’s oncology development programs include sapacitabine, a novel orally-available nucleoside analog that is in Phase III clinical trial for the front-line treatment of acute myeloid leukemia; and Phase II clinical trial for the treatment of myelodysplastic syndromes. It currently has negative earnings. The Company’s oncology development programs also comprise Seliciclib, a first-generation cyclin dependent kinase inhibitor that is in phase I/II combination study with sapacitabine for BRCA mutations; and CYC065, a second generation CDK inhibitor, which is in Phase I clinical trial for solid tumors.

More notable recent Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) news were published by: Finance.Yahoo.com which released: “Could Cyclacel Pharmaceuticals, Inc.’s (NASDAQ:CYCC) Investor Composition Influence The Stock Price? – Yahoo Finance” on April 29, 2019, also Globenewswire.com with their article: “Cyclacel Pharmaceuticals to Release First Quarter 2019 Financial Results – GlobeNewswire” published on May 08, 2019, Seekingalpha.com published: “Cyclacel Pharmaceuticals (CYCC) Presents At BIO CEO & Investor Conference – Slideshow – Seeking Alpha” on February 12, 2019. More interesting news about Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) were released by: Seekingalpha.com and their article: “Cyclacel down 4% on sapacitabine/seliciclib data – Seeking Alpha” published on April 01, 2019 as well as Nasdaq.com‘s news article titled: “Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2018 Financial Results – Nasdaq” with publication date: March 20, 2019.

Reliance Steel & Aluminum Co. (NYSE:RS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.